BioVersys

BioVersys is a multi-asset, clinical-stage biopharmaceutical company focused on the development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant bacteria.

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Beyond the peak season – Greek travel and leisure

How AI has changed who tells your company’s story

The UK government opened the Modernising Corporate Reporting (MCR) consultation in September, proposing a wholesale review of how UK companies communicate with investors and creditors: From annual reports and strategic disclosures to AGMs and digital communications.

Audiovisual

Latest

Starpharma’s Cheryl Maley on DEP HER2-Lu clinical plans and strategic partnerships

Baker Steel Resources Trust – equity proposition

Abcourt Mines – an all-inclusive opportunity: From a small producer to a polymetallic mining camp

About Edison

Corporates

Investors

Careers

BioVersys (SIX: BIOV)

Latest News

Latest Insights

BioVersys — RIV-CARE FPFV raises the bar

BioVersys (SIX: BIOV) – RIV-CARE achieves first patient first visit

BioVersys — Peer-reviewed data reinforce BV100’s potential

BioVersys (SIX: BIOV): Peer-reviewed data support BV100 profile

Share Price Chart

Market Data

Sector

Equity Analyst

Key Management

Research

BioVersys — Poised to unlock value in critical AMR

BioVersys – executive interview

Bull, Bear & Beyond – BioVersys: executive interview

BioVersys — Targeting resistant and threatening indications

Redesigning immunity: The next frontier in immuno-oncology

Edison explains: Investing in health stocks – how policy clarity is opening doors

The CNS renaissance: Innovations are reshaping neurological therapies

Healthcare-focused trusts: A sector on the mend

Outlook for 2024: Life sciences – where has the conviction gone?

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

VolitionRx – Decoding the DNA of cancer

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time